Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey, and is named for Merck Group, founded in Germany in 1668, of whom it was once the American arm. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada.
Company profile
Ticker
MRK, MRK-FP, MRK-PE, MRK-MM
Exchange
Website
CEO
Kenneth Frazier
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Merck & Co. Inc., SCHERING PLOUGH CORP
SEC CIK
Corporate docs
Subsidiaries
7728026 Canada Inc. • Abmaxis Inc. • Acceleron Pharma Inc. • Afferent Pharmaceuticals, Inc. • Agrident GmbH • Agro Verhen B.V. • Allflex Argentina S.A. • Allflex Australia • Allflex (China) Intelligent Technology Co. Ltd. • Allflex dan-mark ApS ...
IRS number
221918501
MRK stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
26 Feb 24
8-K
Departure of Directors or Certain Officers
20 Feb 24
8-K
Merck Announces Fourth-Quarter and Full-Year 2023 Financial Results
1 Feb 24
8-K
Departure of Directors or Certain Officers
28 Nov 23
10-Q
2023 Q3
Quarterly report
3 Nov 23
8-K
Merck Announces Third-Quarter 2023 Financial Results
26 Oct 23
10-Q
2023 Q2
Quarterly report
7 Aug 23
8-K
Merck Announces Second-Quarter 2023 Financial Results
1 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
26 May 23
SD
Conflict minerals disclosure
22 May 23
Transcripts
MRK
Earnings call transcript
2023 Q4
1 Feb 24
MRK
Earnings call transcript
2023 Q3
26 Oct 23
MRK
Earnings call transcript
2023 Q2
1 Aug 23
MRK
Earnings call transcript
2023 Q1
27 Apr 23
MRK
Earnings call transcript
2022 Q4
2 Feb 23
MRK
Earnings call transcript
2022 Q3
27 Oct 22
MRK
Earnings call transcript
2022 Q2
28 Jul 22
MRK
Earnings call transcript
2022 Q1
28 Apr 22
MRK
Earnings call transcript
2021 Q4
3 Feb 22
MRK
Earnings call transcript
2021 Q3
28 Oct 21
Latest ownership filings
4
Harpoon Therapeutics, Inc.
11 Mar 24
4
Caroline Litchfield
15 Feb 24
4
Robert M Davis
15 Feb 24
144
Notice of proposed sale of securities
14 Feb 24
144
Notice of proposed sale of securities
14 Feb 24
144
Notice of proposed sale of securities
14 Feb 24
4
Joseph Romanelli
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
144
Notice of proposed sale of securities
13 Feb 24
144
Notice of proposed sale of securities
13 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 8.67 bn | 8.67 bn | 8.67 bn | 8.67 bn | 8.67 bn | 8.67 bn |
Cash burn (monthly) | (no burn) | 217.50 mm | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | n/a | 1.22 bn | n/a | n/a | n/a | n/a |
Cash remaining | n/a | 7.45 bn | n/a | n/a | n/a | n/a |
Runway (months of cash) | n/a | 34.2 | n/a | n/a | n/a | n/a |
Institutional ownership, Q4 2023
52.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2809 |
Opened positions | 286 |
Closed positions | 523 |
Increased positions | 1028 |
Reduced positions | 1215 |
13F shares | Current |
---|---|
Total value | 134.74 tn |
Total shares | 1.33 bn |
Total puts | 4.68 mm |
Total calls | 2.77 mm |
Total put/call ratio | 1.7 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 244.78 mm | $26.69 tn |
STT State Street | 116.87 mm | $12.83 tn |
Wellington Management | 85.60 mm | $9.33 tn |
FMR | 42.80 mm | $4.67 tn |
MS Morgan Stanley | 40.13 mm | $4.37 tn |
Charles Schwab Investment Management | 36.68 mm | $3.97 tn |
T. Rowe Price | 30.09 mm | $3.28 bn |
NTRS Northern Trust | 28.49 mm | $3.11 tn |
JPM JPMorgan Chase & Co. | 25.41 mm | $2.77 tn |
LGEN Legal & General | 23.49 mm | $2.56 tn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
11 Mar 24 | Merck & Co | Common Stock, par value $0.0001 | Buy | Acquire P | Yes | No | 23 | 21,397,205 | 492.14 mm | 1,000 |
14 Feb 24 | Robert M Davis | Common Stock | Sell | Dispose S | No | No | 125.3993 | 85,021 | 10.66 mm | 348,326.757 |
14 Feb 24 | Robert M Davis | Common Stock | Option exercise | Acquire M | No | No | 73.73 | 85,021 | 6.27 mm | 433,347.757 |
14 Feb 24 | Robert M Davis | Stock Option Common Stock | Option exercise | Dispose M | No | No | 73.73 | 85,021 | 6.27 mm | 96,760 |
13 Feb 24 | Robert M Davis | Common Stock | Sell | Dispose S | No | No | 126.3733 | 25,324 | 3.20 mm | 348,326.757 |
13 Feb 24 | Robert M Davis | Common Stock | Sell | Dispose S | No | No | 125.7431 | 124,676 | 15.68 mm | 373,650.757 |
13 Feb 24 | Robert M Davis | Common Stock | Option exercise | Acquire M | No | No | 73.73 | 108,491 | 8.00 mm | 498,326.757 |
13 Feb 24 | Robert M Davis | Common Stock | Option exercise | Acquire M | No | No | 75.36 | 41,509 | 3.13 mm | 389,835.757 |
13 Feb 24 | Robert M Davis | Stock Option Common Stock | Option exercise | Dispose M | No | No | 73.73 | 108,491 | 8.00 mm | 181,781 |
13 Feb 24 | Robert M Davis | Stock Option Common Stock | Option exercise | Dispose M | No | No | 75.36 | 41,509 | 3.13 mm | 83,020 |
News
US Prescriptions Race For Weight Loss Drugs - Eli Lilly's Zepbound Overtakes Novo Nordisk's Wegovy
18 Mar 24
Newly Diagnosed Cervical Cancer Patients - Merck's Blockbuster Drug Keytruda Plus Chemoradiotherapy Improves Overall Survival
15 Mar 24
Congressional Scrutiny Intensifies On Chinese Biotech Firms: WuXi AppTec Faces Biotech Exodus
14 Mar 24
Market Analysis: Merck & Co And Competitors In Pharmaceuticals Industry
13 Mar 24
Merck Plans To Conduct Clinical Trials Of A Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine And Single-Dose Regimen For GARDASIL®9
13 Mar 24
Press releases
FarmSee Ltd Announces the Completion of a Minority Investment in its Swine Monitoring Platform
15 Mar 24
Merck's KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival (OS) Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
15 Mar 24
Merck Announces Plans to Conduct Clinical Trials of a Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9
13 Mar 24
Merck Completes Acquisition of Harpoon Therapeutics, Inc.
11 Mar 24
Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24
6 Mar 24